CONFERENCES

    Portuguese Society of Pharmacology

    This is an annual conference by Portuguese Society of Pharmacology (A Sociedade Portuguesa de Farmacologia, SPF) focusing on pharmacology with topics ranging from toxicology to cancer pharmacology. The conference is aimed at scientists, academics, researchers, healthcare professionals, regulators, and industry experts, and provides a forum for sharing knowledge and collaborating on new approaches to drug development and regulation.

    53rd SPF Annual Meeting 2023

    Date

    Feb 01, 2023 - Feb 03, 2023

    Location

    Coimbra, Portugal

    Hosted by The Institute of Pharmacology and Experimental Therapy of the Faculty of Medicine of the University of Coimbra (FMUC), this event includes a session presented by Dr. Christelle Haziza from PMI on tobacco harm reduction and non-combustible alternatives.  

    49th SPF Annual Meeting 2019

    Date

    Feb 06, 2019 - Feb 08, 2019

    Location

    Porto, Portugal

    Organised by the Pharmacology and Toxicology Laboratories of the Faculty of Pharmacy of the University of Porto (FFUP), this event is co-hosted with the 18th annual Meeting of Toxicology and the 37th Meeting of Clinical Pharmacology. 

    47th SPF Annual Meeting 2017

    Date

    Feb 03, 2017

    See related presentations

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.